Vanderbilt Ingram Cancer Center

The U.S. Food and Drug Administration (FDA) recently approved ruxolitinib, the first drug for patients with acute graft-versus-host disease (GVHD) who have an inadequate response to steroid treatment. VUMC's Madan Jagasia, MBBS, MS, MMHC, was a lead investigator of the REACH1 trial that was the basis for the FDA approval.

Microbial species in the mouth could be playing a role in colorectal cancer development, according to new research from epidemiologists at VUMC.

Nine years after being diagnosed with metastatic lung cancer, Roszell Mack Jr., 87, still goes into the office every day thanks to a durable response to the immunotherapy pembrolizumab.

Mariana Byndloss, DVM, PhD, has been selected to participate in the Future Research Leaders Conference at the National Institutes of Health.

Bioimpedance spectroscopy (BIS) is better than a tape measure for assessing a woman’s risk for developing lymphedema.

Malignant rhabdoid tumor (MRT) is one of the most aggressive and lethal childhood cancers. Although rare — about 20 to 25 new cases are diagnosed annually in the United States — there is no standard effective treatment for the disease, which is driven by loss of an anti-cancer protein called SNF5. The chances are very small that a child will survive a year after MRT diagnosis.

Tony Hunter, PhD, an internationally recognized leader in the study of cell growth control, will deliver the final spring Flexner Discovery Lecture on Thursday, May 2.